Revenue segments as reported by the company.

Product sales

Royalty, contract and other revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Acquired in-process research and development expenses

Selling, general and administrative

In-process research and development impairment

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Gilead Sciences

Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm's primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases. It offers antiviral products under Harvoni, Genvoya, Epclusa, Truvada, Atripla, Descovy, Stribild, Viread, Odefsey, Complera/Eviplera, Sovaldi, and Vosevi brands. The company was founded by Michael L. Riordan on June 22, 1987 and is headquartered in Foster City, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Gilead Sciences reports robust earnings, eyes pipeline opportunities for growth

Gilead Sciences delivered strong financial performance in Q4 2022, driven by growth in key product sales. Despite facing challenges in the HIV market for Q1 2023, the company remains focused on leveraging opportunities in its pipeline and strategic investments.

Gilead reports strong Q1 sales, focuses on pipeline growth

Gilead Sciences delivered strong sales driven by key products in Q1 2023.
While facing challenges like lower Veklury sales, Gilead maintains revenue guidance.
The company's strengths lie in its pipeline, successful products, and manufacturing capabilities.
Opportunities in new indications and therapies position Gilead for future growth.

Gilead Sciences reports robust Q2 performance and eyes future growth

Gilead Sciences had a strong quarter with growth in sales and positive pipeline updates.
Trodelvy's performance in different markets and potential Medicare coverage are key highlights.
Challenges include unsuccessful trials and addressing revenue aspirations.
Opportunities lie in expanding BD activities and exploring cell therapy beyond oncology.

Gilead Sciences reports robust Q3 performance amidst market challenges

Gilead Sciences demonstrated strong performance in Q3 2023, driven by growth in base business, oncology, and HIV segments.
While facing challenges such as declining Veklury sales and barriers to CART therapy uptake, Gilead is actively addressing opportunities for growth and market expansion.
The company's strengths lie in robust product sales, particularly in Biktarvy and Trodelvy, with a focus on innovation and strategic positioning in key therapeutic areas.
Overall, Gilead's performance reflects resilience and strategic planning amidst evolving market dynamics and competitive landscapes.

Gilead Sciences reports strong 2023 performance, eyes transformative therapies

Gilead Sciences showcased solid performance in 2023 with notable growth in key product sales areas, despite facing challenges in certain clinical trials. The company's strengths lie in its diverse portfolio, pipeline innovation, and commitment to delivering transformative therapies. With a focus on addressing HIV, oncology, and inflammation, Gilead is well-positioned for future growth and success.

Gilead Sciences reports robust Q1 performance and eyes future growth

Gilead Sciences delivered strong Q1 results driven by oncology and HIV product sales.
Challenges include IP R&D charge from Sema Bay acquisition and competitive market dynamics.
Opportunities lie in expanding cell therapy leadership, advancing HIV pipeline, and upcoming pipeline updates.
Overall, Gilead remains focused on growth through innovation and strategic portfolio advancements.

Gilead Sciences reports robust Q3 performance and eyes market expansion

Gilead Sciences' Q3 performance reflects strong revenue growth and market leadership in key segments, supported by successful product launches and strategic initiatives.
The company's focus on innovation, patient-centric approaches, and market expansion bodes well for future growth and competitive positioning.
While challenges in maintaining growth and managing expenses exist, Gilead's proactive stance on addressing market needs and leveraging opportunities positions it for continued success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Gilead Sciences (NASDAQ: GILD) reported quarterly earnings of $1.68 per share on Thursday, which beat the analyst consensus estimate of $1.57 by 7.01%.

Gilead Reports Q1 Earnings Beat, Anticipates Short-Term Impact From Coronavirus

Shares of GILD stock slipped Thursday after the biotech company beat first-quarter estimates, but withheld its outlook due to the pandemic.

Gilead Slides As Biotech Giant Withholds Outlook Due To Pandemic

Gilead Sciences said Thursday that it can produce “several million” rounds of

Gilead says it can produce 'several million' rounds of remdesivir coronavirus treatments next year

Newmont Mining

NRG Energy

These are the top stocks of the entire S&P 500 with the best value, fastest growth, and most momentum for May.

Top Stocks for May 2020

Westport, CT, April  30, 2020  (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (Nasdaq:  BSGM ) today announced that an article titled, “ The IMPDH inhibitor merimepodib provided in combination with the adenosine analogue remdesivir reduces SARS-CoV-2 replication to undetectable levels in vitro”, was submitted to an online peer-reviewed life sciences journal. 

ViralClear Submits In Vitro Data on Merimepodib and Remdesivir Synergistic Activity Against the COVID-19 Novel Coronavirus to a Peer-Reviewed Journal

“There are literally dozens and dozens of investigators around the world. People were starting to leak it.

Report: Fauci Revealed Remdesivir Trial Results To Get Ahead Of Leaks

A large number of biotech companies have been working on developing drugs and vaccine for the novel coronavirus that has infected more than 3,100,000 and claimed 227,000 lives.

Remdesivir Progresses on Coronavirus Trial: Pharma Upbeat

Boeing

Thursday's big stock charts feature names that moved sharply on red-hot news stories
The post 3 Big Stock Charts for Thursday: Gilead Sciences, Boeing, and Nio appeared first on InvestorPlace.
More From InvestorPlace
		
					
				
					America’s #1 Stock Picker Reveals Next 1,000% Winner				
			
					
				
					25 Stocks You Should Sell Immediately				
			
					
				
					#1 Under-the-Radar 5G Stock to Buy Now				
			
					
				
					The 1 Stock All Retirees Must Own

3 Big Stock Charts for Thursday: Gilead Sciences, Boeing, and Nio

Abbott Labs

Novavax

They're battling COVID-19 in different ways. And they each have a lot more going for them than just their coronavirus programs.

Have $3,000 to Invest? Here Are 3 Top Coronavirus Stocks to Buy Right Now.

Apple

Amazon

In the busiest earnings week of the season, Thursday is the biggest act.

Earnings Watch: Apple, Amazon and Gilead take anchor leg of earnings race with a big lead

Experimental antiviral remdesivir holds promise as a treatment for COVID-19 -- but questions remain.

Coronavirus drug remdesivir shows 'clear-cut positive effect' in US trial

An antiviral drug called remdesivir got a strong vote of confidence today from one of the most prominent figures in the battle against the coronavirus outbreak.

Antiviral drug remdesivir takes the spotlight in the search for COVID-19 cures

"This drug makes a big difference, especially if you were worried about a second wave of infections after we reopened the economy," the "Mad Money" host said.

Jim Cramer on Wednesday's rally: 'Remdesivir is just what the doctor ordered'

Gilead Has A Lot Of Explaining To Do Thursday

Gilead: SIMPLE Trial Indicates Remdesivir May Help Severely Ill COVID-19 Patients

President Donald Trump said Wednesday he wants the Food and Drug Administration to move “as quickly as they can” to approve Gilead Sciences’ antiviral drug remdesivir as a treatment for the coronavirus.

Trump wants FDA to move 'as quickly as they can' on remdesivir coronavirus approval

Global biopharmaceutical company Gilead Sciences, Inc. (NASDAQ: GILD) helped spur a rally in stocks Wednesday after results from a trial showed its drug remdesivir could potentially help treat people infected with the coronavirus.

Gilead’s remdesivir dominated headlines on Wednesday: what we know so far

U.S. stock benchmarks added to strong gains Wednesday afternoon to finish sharply higher after Dr.

Dow books 530-point gain as stock-market advance intensifies after Fauci says Gilead coronavirus trial drug is 'quite good news'

Shares of Gilead Sciences Inc. GILD, +6.94% were up 6.8% in trading on Wednesday afternoon.

NYT: FDA may grant emergency authorization to Gilead's remdesivir

The Food and Drug Administration has been in "sustained and ongoing" discussions with Gilead Sciences to make antiviral drug remdesivir available to Covid-19 patients "as quickly as possible, as appropriate," the agency said.

FDA in 'ongoing' talks with Gilead to make remdesivir available to coronavirus patients 'as quickly as possible'

SPDR Dow Jones Industrial Average ETF

Invesco QQQ

SPDR S&P 500 ETF Trust

Stocks are making big moves today amid positive news from Gilead Sciences that a vaccine for the coronavirus could be in the works. The biotech company’ stock climbed 6.5% in midday trading Wednesday as the company said that preliminary results of a coronavirus drug trial demonstrated at least 50% of patients treated with a five-day dosage of [.

Stocks And Index ETFs Rally On Vaccine Hopes From Gilead

Marriott

Park Hotels & Resorts

Wyndham Hotels & Resorts Inc

Wyndham Destinations Inc

Will Gilead's new drug reopen America for business -- and hotel stays?

Why Hotel Stocks Are Surging Today

Fauci Says Remsdesivir Reduces Recovery Time For Coronavirus Patients

Gilead released more positive data on its Covid-19 treatment, remdesivir, laying the groundwork for bigger gains ahead for GILD stock. 
The post Buy Gilead Stock Because Remdesivir Is a Covid-19 Game-Changer appeared first on InvestorPlace.

Buy Gilead Stock Because Remdesivir Is a Covid-19 Game-Changer

Additional details are expected later Wednesday.

News for Gilead Sciences Stock (GILD)